Loading...
XSHE000538
Market cap14bUSD
Dec 24, Last price  
60.25CNY
1D
0.93%
1Q
17.17%
Jan 2017
-20.51%
Name

Yunnan Baiyao Group Co Ltd

Chart & Performance

D1W1MN
XSHE:000538 chart
P/E
26.04
P/S
2.73
EPS
2.31
Div Yield, %
2.58%
Shrs. gr., 5y
0.03%
Rev. gr., 5y
7.93%
Revenues
39.11b
+7.19%
1,832,312,1962,448,395,0213,200,335,5134,115,716,8995,723,198,6677,171,784,04310,075,437,83411,312,322,43213,686,824,52515,814,790,88018,814,366,37220,738,126,20522,410,654,40424,314,614,04426,708,213,48729,664,673,86832,742,766,76336,373,919,01636,488,372,64939,111,292,156
Net income
4.09b
+36.41%
171,348,717230,370,274276,395,341336,790,481465,420,155603,719,565926,168,5801,210,908,6661,582,515,8432,321,453,7872,506,076,5012,770,841,4012,919,876,8123,144,981,4293,306,564,3174,183,727,5535,516,072,1782,804,916,7153,001,125,8874,093,782,074
CFO
3.50b
+9.14%
169,346,918286,277,104292,162,70060,503,123806,896,878460,548,807432,083,8840794,948,911341,641,5861,586,864,1792,179,500,4012,984,757,6821,155,689,9482,629,807,2362,104,744,8253,828,906,6325,223,278,2823,209,410,0323,502,742,339
Dividend
May 10, 20242.077 CNY/sh
Earnings
Mar 28, 2025

Profile

Yunnan Baiyao Group Co.,Ltd engages in the pharmaceutical business in China and internationally. It provides health products, drugs, medical instruments, Chinese medicine resources, and tea. The company offers its products under the Yunnan Baiyao, Yunfeng, Tong Qiaoqiao, Yunjian, Life, Jinkoujian, Langjian, Yangyuanqing, Caizhiji, Baiyao Health, Leopard Seven, Qiancaotang, Qiancao Meizi, and Tianzihong brand names. Yunnan Baiyao Group Co., Ltd. was founded in 1902 and is based in Kunming, China.
URL
http://www.yunnanbaiyao.com.cn
IPO date
Dec 15, 1993
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
39,111,292
7.19%
36,488,373
0.31%
36,373,919
11.09%
Cost of revenue
32,365,493
31,642,188
31,449,326
Unusual Expense (Income)
NOPBT
6,745,799
4,846,185
4,924,593
NOPBT Margin
17.25%
13.28%
13.54%
Operating Taxes
695,451
536,593
685,310
Tax Rate
10.31%
11.07%
13.92%
NOPAT
6,050,349
4,309,592
4,239,283
Net income
4,093,782
36.41%
3,001,126
7.00%
2,804,917
-49.15%
Dividends
(2,747,626)
Dividend yield
3.13%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,747,304
1,944,739
1,822,559
Long-term debt
346,795
573,667
429,660
Deferred revenue
238,811
178,622
199,182
Other long-term liabilities
653,123
671,003
659,488
Net debt
(26,912,618)
(22,308,989)
(21,338,802)
Cash flow
Cash from operating activities
3,502,742
3,209,410
5,223,278
CAPEX
(575,507)
Cash from investing activities
518,581
3,998,696
Cash from financing activities
(2,920,712)
FCF
5,544,859
6,892,488
3,240,680
Balance
Cash
17,029,532
15,471,836
23,591,021
Long term investments
11,977,185
9,355,559
Excess cash
27,051,152
23,002,976
21,772,325
Stockholders' equity
22,437,773
21,055,761
20,386,452
Invested Capital
20,281,273
20,044,197
20,456,032
ROIC
30.01%
21.28%
21.65%
ROCE
15.76%
11.76%
12.05%
EV
Common stock shares outstanding
1,787,678
1,579,540
1,801,323
Price
49.15
-9.58%
54.36
-48.06%
104.65
-7.88%
Market cap
87,864,362
2.33%
85,863,793
-54.45%
188,508,412
-7.39%
EV
60,977,982
63,578,128
167,377,292
EBITDA
7,118,996
5,299,794
5,272,800
EV/EBITDA
8.57
12.00
31.74
Interest
58,589
67,850
51,660
Interest/NOPBT
0.87%
1.40%
1.05%